The poor prognosis results from the fact that traditional immunosuppressive treatment is frequently ineffective in patients with anti-MDA5+ DM with interstitial lung disease, especially rapidly progressive interstitial lung disease, which is a significant factor contributing to mortality. Here, IFIH1 is linked to interstitial lung disease.